Comparative Pharmacology
Head-to-head clinical analysis: LEVLITE versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVLITE versus NORINYL 1 80 21 DAY.
LEVLITE vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive